Elan presents data on new Alzheimers drug

Elan Corporation and Wyeth Pharmaceuticals last night announced key findings from a clinical trial of a new Alzheimers treatment, AN-1792, at the International Conference on Alzheimers Disease and Related Disorders in Philadelphia.

Although dosing with AN-1792 was halted in January 2002 after reports of encephalitis in some patients, the the patients were followed in the study until December 2002.